Precision medicine promises the right treatment for the right patient. But what happens when the drug is ready and the test needed to identify eligible patients is not? For pharmaceutical manufacturers and their testing partners, companion diagnostics commercialization is becoming an increasingly important part of launching precision medicines successfully. Yet the two sides often operate on different timelines, with different financial incentives and regulatory challenges. When those differences delay patient access, the question becomes unavoidable: who is responsible for the launch failure?
Table of Contents
- Why Drug and Diagnostic Launches Fall Out of Sync
- Who Pays for Companion Diagnostic Market Readiness?
- Aligning Commercial Incentives and Launch Timelines
- Measuring Success Beyond Drug Approval
- Conclusion
- Frequently Asked Questions
Why Drug and Diagnostic Launches Fall Out of Sync
A precision therapy cannot reach its full potential if physicians cannot identify the patients who qualify for treatment. However, pharmaceutical companies and diagnostic manufacturers often operate under very different business models, regulatory requirements, and financial pressures.
Drug manufacturers invest heavily in clinical development, market access, sales teams, and promotional campaigns. Meanwhile, diagnostic companies must validate their tests, establish laboratory capacity, train providers, and navigate reimbursement requirements.
According to the FDA’s guidance on companion diagnostic devices, companion tests and their corresponding therapies should generally receive regulatory authorization at approximately the same time. However, simultaneous approval does not guarantee that testing will be widely available when treatment launches.
A diagnostic may be approved but unavailable across major treatment centers. Laboratories might lack equipment, trained personnel, or dependable insurance reimbursement. Furthermore, physicians may not know when to order testing or how to interpret the results.
Consider a hypothetical oncology treatment approved for patients with a specific genetic mutation. The pharmaceutical company launches its marketing campaign, but only a limited number of laboratories can perform the required test.
Consequently, eligible patients may remain unidentified while treatment adoption falls behind projections. The drug is commercially ready, but the system needed to find patients is not.
This disconnect creates more than an operational inconvenience. It can undermine launch investments, frustrate healthcare providers, and delay access to potentially beneficial treatments.
Who Pays for Companion Diagnostic Market Readiness?
Getting companion diagnostic tests into everyday clinical use raises a difficult financial question: who should pay for the infrastructure needed to identify eligible patients?
Pharmaceutical manufacturers benefit when appropriate patients receive biomarker testing. Diagnostic companies, however, generate revenue through testing products or services rather than prescription volume. As a result, both partners may benefit from broader testing access without agreeing on who should finance it.
A pharmaceutical company might justify significant spending on physician education because successful testing supports therapy adoption. Meanwhile, its diagnostic partner may struggle to recover the cost of expanding laboratory operations for a relatively small patient population.
Additionally, uncertain reimbursement can discourage laboratories from adopting new testing technologies. Research on diagnostic reimbursement and personalized medicine has identified inconsistent coverage and limited supporting evidence as barriers to the adoption of drug-diagnostic combinations.
Therefore, successful partnerships need financial agreements that extend beyond developing and approving the diagnostic itself.
Manufacturers and testing partners should establish clear responsibilities for provider education, laboratory onboarding, technical support, and market access planning. These arrangements must also comply with applicable healthcare laws and promotional requirements.
For example, companies can coordinate appropriate educational programs that explain biomarker testing requirements without improperly influencing clinical decisions. Likewise, market access teams can work with payers and laboratory networks before launch to identify coverage obstacles.
Ultimately, the commercial relationship must address not only who develops the test, but also who makes testing practical in everyday care.
Aligning Commercial Incentives and Launch Timelines
The best strategies for bringing companion diagnostics to market begin long before a drug receives regulatory approval. Instead of treating diagnostic availability as a secondary milestone, pharmaceutical companies should make testing readiness a central part of launch planning.
Doing so requires coordination across regulatory affairs, medical affairs, marketing, market access, diagnostic manufacturers, and laboratory networks. However, coordination means little without clearly assigned responsibilities.
Partners should establish measurable milestones covering laboratory availability, reimbursement preparation, physician education, and testing turnaround times. Additionally, commercial agreements should clarify what happens when either partner misses an important deadline.
A shared launch dashboard can help both organizations identify problems before they affect patients. For instance, declining laboratory readiness or delayed payer coverage decisions might trigger additional support or revised launch activities.
Pharmaceutical marketers also play an important role in supporting appropriate testing awareness. Educational campaigns can help healthcare professionals understand biomarker testing requirements and their relevance to treatment decisions.
Targeted digital outreach may help companies connect with relevant healthcare professionals. For pharmaceutical marketing teams evaluating these strategies, Pharma Marketing Network provides industry coverage and perspectives on pharmaceutical marketing practices.
Organizations exploring healthcare-focused digital advertising can also learn about available marketing capabilities through eHealthcare Solutions.
Nevertheless, even the strongest promotional strategy cannot compensate for a diagnostic that patients cannot access. Launch calendars should reflect actual testing capacity rather than optimistic assumptions about future readiness.
Measuring Success Beyond Drug Approval
Pharmaceutical launches traditionally emphasize regulatory approval, prescription growth, market share, and revenue. Yet precision medicine requires another layer of commercial measurement.
A successful launch should also evaluate how reliably the healthcare system identifies patients who may benefit from treatment.
For example, manufacturers and diagnostic partners can monitor testing adoption, laboratory coverage, turnaround times, and reimbursement barriers. They should also examine where delays occur between test ordering, receiving results, and making treatment decisions.
These measures provide early warning signs when commercial plans are moving faster than diagnostic access. Furthermore, shared performance reviews can help partners distinguish operational problems from broader challenges involving clinical adoption.
Any collection or analysis of patient-related testing information must follow applicable privacy, consent, and data protection requirements.
Companies should also establish procedures for escalating problems when testing access falls below agreed expectations. If laboratories cannot handle demand, diagnostic partners may need additional operational resources. Meanwhile, insufficient physician awareness may call for better coordinated educational efforts.
Importantly, responsibility should follow the actual cause of the problem rather than automatically falling on one partner.
A drug launch should not be considered fully successful simply because the medicine reached the market on schedule. The testing pathway must also work for the patients and healthcare professionals who depend on it.
Conclusion
The success of precision medicine depends on more than developing effective therapies. It also requires a dependable system for identifying the patients who need them.
Bringing diagnostic tests to market must become a shared responsibility, not an afterthought handled separately from the drug launch.
Pharmaceutical manufacturers and diagnostic partners need aligned timelines, clear financial responsibilities, measurable access goals, and consistent communication. Without these elements, patients may face delays while commercial performance suffers.
Ultimately, the question is not simply who owns the diagnostic. It is who takes responsibility for making the entire treatment pathway work.
Frequently Asked Questions
What does it take to bring a companion diagnostic to market?
Bringing a companion diagnostic to market involves test development, regulatory authorization, laboratory adoption, reimbursement planning, and healthcare provider education. Successful commercialization also requires coordination with the pharmaceutical company developing the corresponding treatment.
Why do companion diagnostics sometimes lag behind drug launches?
Diagnostic companies and pharmaceutical manufacturers face different regulatory processes, financial incentives, and operational requirements. Consequently, testing infrastructure may develop more slowly than drug launch plans, even when regulatory approvals occur around the same time.
Who should pay for companion diagnostic testing infrastructure?
Funding responsibilities depend on commercial agreements and applicable regulations. However, both pharmaceutical manufacturers and diagnostic companies have reasons to support laboratory readiness, testing education, and appropriate patient access.
How can pharmaceutical companies improve diagnostic launch coordination?
Companies can establish shared launch milestones, assign responsibilities, engage payers early, and monitor laboratory readiness. Additionally, regular joint reviews can identify barriers before they disrupt testing access or treatment decisions.
What happens when diagnostic testing is unavailable at launch?
Eligible patients may experience delays in diagnosis or treatment selection. Meanwhile, pharmaceutical companies may see slower therapy adoption, and diagnostic partners may face additional operational and commercial pressure.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
